About

BiomimX S.r.l. is a pioneer in proposing the next generation of clinically relevant in–vitro models: human, dynamic, 3D. BiomimX offers high-content, controlled and reliable in vitro setups (Beating Organs on Chip) to achieve a deeper insight on human biology, pivotal for the effective discovery of new therapies. Every tissue in the body is subjected to motion: Beating Organs on Chip provide controlled mechanical stimulation to 3D cell culture, developing more reliable, fast responsive, and predictive in vitro physiological or pathological models to profile, expand and explore new therapies for complex diseases. BiomimX’s portfolio comprises among other organs, uHeart, uKnee, uScar, uGut, Liver-Heart, uLung. About BiomimX BiomimX S.r.l. is a pioneer in Organ on a Chip (OoC) technology, producing the next generation of clinically relevant in-vitro models for pharmaceutical drug discovery and testing. Our proprietary platform integrates microfluidics, 3D cell culture, live human cells, and mechanical stimuli to produce "Beating Organs on a Chip" . These recapitulate, with unprecedented precision and predictability, clinically relevant models reflective of human physiology and pathology. Pharma R&D is an area where animal models continue to fall short due to lack of translatability and/or lack of relevant models. Regulatory agencies in the US and Europe are now moving forward to encourage biopharma's use of more predictive non-animal models. BiomimX is poised to be a leader in this space and has gained early traction with industry. Every tissue in the body is subject to motion. The advantage of BiomimX approach is our patented uBeat platform which provides 3D microtissues with controlled mechanical stimulation. Current competitors are limited to 2D cultures without mechanical stimulation and poor scalability. Our models overcome this with 3D culture, mechanical stimulation, and materials allowing for enhanced scalability. This provides a window into human organs and complex disease, without involving animals. The result is a more reliable, responsive, and predictive in vitro model to investigate new therapies. BiomimX lead model is uHeart (Visone, Tox Sciences, 2023; +4 additional cardiac publications), a functional beating heart on a chip for cardiotoxicity and safety testing early in the pipeline. uHeart was recently qualified with 12 drugs as a predictor of functional cardiotoxicity, showing 83.3% sensitivity, 100% specificity, and 91.6% accuracy. Our pipeline includes a range of predictive physiological and pathological models. uKnee (Occhetta, Nature Biomed Eng, 2019; +2 additional OA publications) has successfully supported a recent IND. Other key models include uScar (fibrosis; Visone, Adv Health Mat, 2023), uGut (Ballerini, Nature Biomed Eng, 2025), uLung and uLiver-Heart (Ferrari, Adv Mat Tech, 2023). The company's founders have deep expertise in microfluidics, microtechnology, translational science, and advanced 3D in-vitro cell culture technologies. Founding members also serve in academia and notable leadership roles for key societies in the field, including Chair and Board Member of the European Organ on Chip Society. In addition, they are currently communicating with the Innovation Task Force (ITF) of EMA regarding BiomimX models. They have over 20+ publications in the field and a strong track record of EU grant success aimed at forwarding the field of OoC. The company is revenue producing with global biopharma and CROs as clients and aims to revolutionize the way new drugs are tested.